Gilead Sciences, Inc. (GILD) Holdings Reduced by New Jersey Better Educational Savings Trust

New Jersey Better Educational Savings Trust lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 25.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,000 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the quarter. New Jersey Better Educational Savings Trust’s holdings in Gilead Sciences were worth $425,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares in the last quarter. Penserra Capital Management LLC lifted its position in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares in the last quarter. Webster Bank N. A. lifted its position in shares of Gilead Sciences by 51.7% during the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 624 shares in the last quarter. American Beacon Advisors Inc. acquired a new stake in shares of Gilead Sciences during the first quarter worth about $143,000. Finally, Welch Group LLC lifted its position in shares of Gilead Sciences by 9.7% during the first quarter. Welch Group LLC now owns 2,857 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 252 shares in the last quarter. 73.98% of the stock is currently owned by institutional investors.

In related news, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the transaction, the chief financial officer now directly owns 43,352 shares in the company, valued at approximately $3,684,920. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP James R. Meyers sold 60,000 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $83.19, for a total value of $4,991,400.00. Following the transaction, the executive vice president now owns 62,715 shares of the company’s stock, valued at $5,217,260.85. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 486,819 shares of company stock valued at $39,298,919. 1.30% of the stock is owned by company insiders.

Several brokerages have recently issued reports on GILD. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Thursday, August 31st. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price target on the stock. in a research report on Monday, August 28th. Cowen and Company reissued an “outperform” rating and set a $90.00 price target on shares of Gilead Sciences in a research report on Wednesday, July 5th. Finally, Wells Fargo & Company increased their price target on shares of Gilead Sciences from $73.00 to $81.00 and gave the stock a “market perform” rating in a research report on Wednesday, September 6th. Twelve equities research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $85.66.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 83.04 on Wednesday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27. The company’s 50 day moving average price is $81.55 and its 200 day moving average price is $71.93. The firm has a market capitalization of $108.44 billion, a P/E ratio of 9.02 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm’s revenue was down 8.2% on a year-over-year basis. During the same period in the prior year, the business earned $3.08 EPS. On average, analysts expect that Gilead Sciences, Inc. will post $8.76 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were paid a dividend of $0.52 per share. The ex-dividend date was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.50%. Gilead Sciences’s payout ratio is currently 22.58%.

COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Holdings Reduced by New Jersey Better Educational Savings Trust” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright a

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares in the last quarter. Penserra Capital Management LLC lifted its position in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares in the last quarter. Webster Bank N. A. lifted its position in shares of Gilead Sciences by 51.7% during the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 624 shares in the last quarter. American Beacon Advisors Inc. acquired a new stake in shares of Gilead Sciences during the first quarter worth about $143,000. Finally, Welch Group LLC lifted its position in shares of Gilead Sciences by 9.7% during the first quarter. Welch Group LLC now owns 2,857 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 252 shares in the last quarter. 73.98% of the stock is currently owned by institutional investors.

In related news, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the transaction, the chief financial officer now directly owns 43,352 shares in the company, valued at approximately $3,684,920. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP James R. Meyers sold 60,000 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $83.19, for a total value of $4,991,400.00. Following the transaction, the executive vice president now owns 62,715 shares of the company’s stock, valued at $5,217,260.85. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 486,819 shares of company stock valued at $39,298,919. 1.30% of the stock is owned by company insiders.

Several brokerages have recently issued reports on GILD. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Thursday, August 31st. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price target on the stock. in a research report on Monday, August 28th. Cowen and Company reissued an “outperform” rating and set a $90.00 price target on shares of Gilead Sciences in a research report on Wednesday, July 5th. Finally, Wells Fargo & Company increased their price target on shares of Gilead Sciences from $73.00 to $81.00 and gave the stock a “market perform” rating in a research report on Wednesday, September 6th. Twelve equities research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $85.66.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 83.04 on Wednesday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27. The company’s 50 day moving average price is $81.55 and its 200 day moving average price is $71.93. The firm has a market capitalization of $108.44 billion, a P/E ratio of 9.02 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm’s revenue was down 8.2% on a year-over-year basis. During the same period in the prior year, the business earned $3.08 EPS. On average, analysts expect that Gilead Sciences, Inc. will post $8.76 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were paid a dividend of $0.52 per share. The ex-dividend date was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.50%. Gilead Sciences’s payout ratio is currently 22.58%.

COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Holdings Reduced by New Jersey Better Educational Savings Trust” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://ledgergazette.com/2017/10/11/gilead-sciences-inc-gild-holdings-reduced-by-new-jersey-better-educational-savings-trust.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply